Complete coverage on

Schering-Plough Corporation

Latest Stories

CNNMoney: Stocks recharge the advanceupdated: Tue Apr 21 2009 17:48:00

Stocks gained Tuesday, rebounding after the previous session's rally as worries about corporate results were countered by renewed hopes that the financial sector is closer to stabilizing.

Fortune: Big Pharma's new landscapeupdated: Thu Mar 12 2009 12:25:00

When Merck's $41 billion acquisition of Schering-Plough was announced Monday, it confirmed a major trend toward consolidation in Big Pharma.

CNNMoney: For Dow, another 12-year lowupdated: Mon Mar 09 2009 18:18:00

Stocks tumbled Monday, with the Dow and S&P 500 ending at fresh 12-year lows, as Merck's $41 billion purchase of Schering-Plough failed to distract investors from worries about the economy.

CNNMoney: Merck and Schering-Plough in $41B mergerupdated: Mon Mar 09 2009 12:47:00

Drugmaker Merck & Co. announced Monday that it has agreed to acquire rival Schering-Plough Corp. in a deal worth $41.1 billion.

CNNMoney: Stocks in rebound modeupdated: Mon Mar 09 2009 10:22:00

Stocks turned higher Monday morning as investors considered Merck's $41 billion purchase of Schering-Plough and opted to scoop up shares hit in the recent selloff.

Merck, Schering-Plough in $41 billion mergerupdated: Mon Mar 09 2009 08:15:00

Pharmaceuticals giants Merck and Schering-Plough are planning to merge their operations under the name Merck in a deal worth $41.1 billion.

CNNMoney: Stocks stage rallyupdated: Tue Feb 03 2009 17:57:00

Stocks rallied Tuesday, erasing morning losses, as investors focused on the day's positive earnings reports and a surprise rise in a key measure of home sales.

CNNMoney: Stocks shake off jobs, GMupdated: Fri Aug 01 2008 08:52:00

U.S. stock futures rebounded Friday following a better-than-expected July employment report and even as General Motors booked a nearly $16 billion loss.

CNNMoney: Stocks retreat slightlyupdated: Mon Jul 21 2008 17:53:00

Stocks closed modestly lower Monday, as rising oil prices and concerns in the tech and drug sectors overpowered a better-than-expected earnings report from Bank of America.

CNNMoney: Stocks poised to rallyupdated: Mon Jul 21 2008 08:26:00

Stock futures climbed Monday morning as investors cheered better-than-expected earnings from Bank of America and the announcement of a deal between Yahoo and activist investor Carl Icahn.

Fred Hassan, CEO, Schering-Ploughupdated: Mon Apr 28 2008 03:44:00

CNN's Maggie Lake gets advice from Fred Hassan, CEO of Schering-Plough, in ''The Boardroom.''

The Fred Factor: Fred Hassanupdated: Mon Apr 28 2008 03:44:00

If your drug company is on its death-bed, this is the man you want as your corporate doctor. He's Fred Hassan, the CEO of drug giant Schering-Plough. In the past 25 years, he has turned around his fair share of ailing pharmaceutical firms, including the recovery and subsequent 56 billion dollar sale of Pharmacia. He's so renowned within his industry that they coined a phrase for his brand of management: "The Fred Factor." Hassan tells The Boardroom's Maggie Lake how he is able to assess, diagnose and cure.

Schering-Plough factsupdated: Mon Apr 28 2008 03:42:00

Based in New Jersey, USA, Schering-Plough is a pharmaceutical company that employs some 55,000 people, operating in more than 140 countries worldwide. Conducting research in the areas of cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health, its best-selling products are Vytorin, Zetia, Remicade and Nasonex.

CNNMoney: Stocks inch higherupdated: Thu Apr 03 2008 17:50:00

Stocks inched higher Thursday, as investors continued to bet that the worst of the credit crisis is behind the market. However, gains were limited by some jitters ahead of Friday's big monthly jobs report.

CNNMoney: Stocks up day, down quarterupdated: Mon Mar 31 2008 17:55:00

Falling oil prices helped lift stocks Monday, at the end of an otherwise abysmal quarter on Wall Street, marred by fears of a recession amid the housing crisis and credit market fallout.

CNNMoney: Big Pharma opens wallet to Demsupdated: Fri Mar 07 2008 14:40:00

Democrats have long served as the traditional enemy of Big Pharma, but in this presidential campaign, the left is taking the lion's share of drugmaker money.

Fortune: Cholesterol skeptics have their dayupdated: Wed Feb 06 2008 16:46:00

Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.

Saving money on prescriptionsupdated: Mon Jan 14 2008 10:18:00

Dr. Sanjay Gupta talks about saving money on prescription drugs with Open House host Gerri Willis.

CNNMoney: Tech stocks lead comeback tryupdated: Mon Oct 22 2007 14:04:00

Technology shares bounced Monday, helping the broader market erase losses, as investors tiptoed back into stocks after last week's big selloff.

CNNMoney: Stocks' sour startupdated: Mon Oct 22 2007 09:32:00

U.S. stocks slipped at the start of trading Monday amid continuing concerns about the economy, corporate earnings and the price of oil.

CNNMoney: SEC asks top firms about exec payupdated: Fri Aug 31 2007 08:12:00

The Securities and Exchange Commission has asked the top brass of nearly 300 U.S. companies to better explain the pay packages of top executives, according to a report Friday.

Fortune: How Big Pharma learned to shareupdated: Thu Aug 30 2007 22:50:00

Sharing is not something most scientists do well. It makes sense. In the laboratory, valuable intellectual property flows from each new discovery. It's the coin of the realm, and as such researchers guard it closely.

CNNMoney: Schering-Plough profits riseupdated: Sun Jul 22 2007 21:50:00

Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.

CNNMoney: Strong start for stocksupdated: Sun Jul 22 2007 21:48:00

Stocks got off to a higher start Monday, helped by some surprisingly strong earnings from Dow component Merck and some dealmaking activity.

Money Magazine: Don't count out the bullupdated: Mon Jun 11 2007 09:43:00

Are you scared yet? After enjoying records for the Dow and the S&P throughout the spring, investors have faced some rough selloffs in June.

CNNMoney: The next big business ideaupdated: Wed Apr 25 2007 11:31:00

A cure for lower back pain could be the next big business idea - at least that's what a panel of judges thought when they picked the winner of the University of Pennsylvania Wharton School's business plan competition Tuesday.

CNNMoney: Thursday's moversupdated: Thu Apr 19 2007 12:46:00

The following are some of Thursday's most actively traded stocks:

CNNMoney: Pity the poor pharmaceutical sales repupdated: Mon Apr 02 2007 15:33:00

It's hard out there for drug sales reps--particularly if they work in places where gaining access to doctors is becoming increasingly difficult.

CNNMoney: Big Pharma teaches old drugs new tricksupdated: Wed Mar 21 2007 12:02:00

As Big Pharma faces patent expirations on some of its most lucrative drugs, the industry is trying to reinvigorate sales by finding creative ways to land new patents - but on the same old drugs.

CNNMoney: Stocks on the move Fridayupdated: Fri Mar 16 2007 10:25:00

The following shares were among the most actively traded Friday:

CNNMoney: Stocks on the move Mondayupdated: Mon Mar 12 2007 10:41:00

The following shares were among the most actively traded Monday:

CNNMoney: Stocks in seesaw modeupdated: Mon Mar 12 2007 10:19:00

Stocks struggled for direction Monday morning as investors weighed a rash of merger and acquisition news with the latest worries about the subprime mortgage lenders.

CNNMoney: Stocks in early struggleupdated: Mon Mar 12 2007 09:31:00

Stocks were choppy Monday morning as lower oil prices and some merger news vied with ongoing worries about the subprime mortgage lenders and some investor reluctance after last week's advance.

CNNMoney: Subprime subdues stocksupdated: Mon Mar 12 2007 09:24:00

U.S. stocks were little changed at Monday's open as concerns about the financial sector in the wake of the latest New Century news overshadowed a slew of deals.

CNNMoney: ALK-Abello soars on Schering-Plough dealupdated: Wed Jan 03 2007 10:01:00

STOCKHOLM -(Dow Jones)- Danish vaccine manufacturer ALK-Abello A/S (ALK-B.KO) said Wednesday it has signed a deal with Schering-Plough Corp. (SGP) of the U.S. to develop its tablet-based allergy vaccines for North America, sending shares up as much as 17% in early trading.

CNNMoney: Novartis poised to lead pharma packupdated: Wed Jan 03 2007 08:57:00

Novartis could be the hottest drug giant in 2007, analysts say, with Schering-Plough and Eli Lilly & Co. not far behind.

Fortune: Schering-Plough's Carrie Cox Named One of FORTUNE's 50 Most Powerful Womenupdated: Thu Oct 19 2006 12:32:00

Carrie Cox, the 49-year-old EVP; President, Global Pharmaceuticals of Schering-Plough, ranks No. 39 on Fortune's 2006 list of 50 Most Powerful Women.

CNNMoney: Report: Schering ponders possible mergerupdated: Fri Sep 15 2006 08:04:00

The drug giant Schering-Plough is seriously considering approaching Bristol-Myers with a merger offer, according to a news report.

CNNMoney: Schering settles sales probe for $435 millionupdated: Tue Aug 29 2006 11:03:00

Schering-Plough said Tuesday it settled a criminal investigation into its sales practices and agreed to pay $435 million in fines and damages.

CNNMoney: Schering-Plough's cholesterol problemupdated: Tue Aug 08 2006 09:46:00

Drugmaker Schering-Plough may have wowed investors with strong second-quarter earnings - but the company has a cholesterol problem.

CNNMoney: Stocks rise on M&A newsupdated: Mon Jul 24 2006 09:16:00

Stocks jumped at the open Monday, with a pair of big mergers and a pullback in oil prices inspiring investors to scoop up beaten-down shares after last week's pummeling.

CNNMoney: Drug industry faces tough second quarterupdated: Wed Jul 12 2006 10:24:00

Big Pharma is feeling the squeeze as name-brand drugs go off patent, which is why analysts are expecting a flat or modest second quarter for most of the biggest U.S. drug makers.

CNNMoney: Telecoms top High Court to-do listupdated: Mon Jun 26 2006 10:08:00

The Supreme Court Monday agreed to consider an appeal by the largest U.S. telephone carriers seeking the dismissal of a class-action antitrust suit against them.

CNNMoney: When it comes to Sepracor, buyers bewareupdated: Tue Jun 20 2006 14:09:00

Pfizer and Schering-Plough could easily snap up the smaller drugmaker Sepracor but industry analysts say risks to its two products would limit any potential gains.

CNNMoney: Vytorin is better than Crestor, says study from Merck, Schering-Ploughupdated: Mon Jun 19 2006 06:00:00

Merck and Schering-Plough announced a study on Sunday showing that their combination drug Vytorin is better at lowering cholesterol than competing drug Crestor from AstraZeneca.

CNNMoney: Glaxo to remain the asthma kingupdated: Fri May 12 2006 15:09:00

Allergy season is in full swing and, in the $25 billion market for respiratory drugs, GlaxoSmithKline is likely to hold its throne as the asthma king for this season and years to come, despite growing competition.

CNNMoney: Schering: A diamond in the roughupdated: Tue May 02 2006 06:06:00

Now that the nation's big drugmakers have reported mostly strong first-quarter results, how do things look going forward?

Fortune: Schering-Plough ranks No. 250 on the 2006 FORTUNE 500updated: Thu Apr 27 2006 13:37:00

Schering-Plough ranks no. 250 on this year's list of the FORTUNE 500, with $9,508 million in revenues, up 14.9% from the previous year. The Kenilworth, N.J.-based company was ranked no. 264 on the 2005 list. Its 2005 profits were $269 million.

CNNMoney: Strong results a mixed bag for drug stocksupdated: Thu Apr 20 2006 16:35:00

Big drugmakers put up mostly strong earnings this week, triggering a variety of reactions on the stock market and a mixed bag of analyst expectations for the year.

CNNMoney: Schering-Plough's big bet against Pfizerupdated: Wed Mar 15 2006 10:12:00

Schering-Plough, once the troubled child of the drug industry, is making a comeback with a hot new drug.

CNNMoney: Gaining at the openupdated: Mon Oct 24 2005 09:25:00

Falling oil prices and strong earnings from the drugmaker were among the factors boosting stocks Monday morning.

CNNMoney: Top firms for working moms unveiledupdated: Mon Sep 12 2005 10:54:00

Three drugmakers are among the companies named to an annual list of the top 10 family-friendly employers unveiled Monday.

CNNMoney: Drug makers: Take two and run awayupdated: Tue Jul 19 2005 09:33:00

If you're hoping for some good results from the drug sector this week, take an aspirin. With two exceptions, the Street expects the earnings pain among drug makers to continue.

CNNMoney: New profit twist for drugmakersupdated: Wed May 11 2005 16:18:00

Drugmakers rue the day when patents expire on blockbuster products, but some companies have found ways to relieve the pain of patent loss and wring more sales out of name brands.

CNNMoney: Albertson's acts on 'meth' makersupdated: Mon Apr 25 2005 08:57:00

Albertson's Inc., the food and drug retailer, announced Monday that certain over-the-counter cold medicines will now be sold from behind the pharmacy counter, because the key ingredient is used to manufacture illegal drugs.

CNNMoney: PETA courts shareholdersupdated: Wed Mar 23 2005 08:03:00

People for the Ethical Treatment of Animals (PETA), citing recent Securities and Exchange Commission rulings, said Wednesday that the boards of General Electric and two other companies must allow shareholders to vote on resolutions seeking to replace "painful and deadly" animal testing with more humane alternatives.

CNNMoney: Stocks to watch Fridayupdated: Thu Feb 05 2004 17:25:00

The earnings parade continued after the closing bell Thursday as Electronic Data Systems, John Hancock and Maxim Integrated Products all reported quarterly results.

CNNMoney: When will big pharma's time come?updated: Thu Jan 29 2004 10:24:00

Are the "big pharmas" finally ready to move up from the back of the pack?

CNNMoney: Stocks mixed at openupdated: Mon Jan 26 2004 09:13:00

U.S. stocks were mixed early Monday as investors geared up for quarterly earnings reports from roughly 30 percent of the Standard & Poor's 500 due this week.

CNNMoney: Stocks try to reboundupdated: Mon Jan 26 2004 05:31:00

U.S. stocks, fresh off their first losing week of 2004, will be subject to more corporate quarterly results and the December existing home sales figures as the investing week starts Monday.

Money Magazine: Funds: A knack for discoveryupdated: Thu Nov 06 2003 17:29:00

In an industry characterized by change, Samuel Isaly has been a rare constant.

Money Magazine: A Knack For Discovery Veteran fund manager Samuel Isaly of Eaton Vance Worldwide Health Sciences has a nose updated: Sat Nov 01 2003 00:01:00

In an industry characterized by change, Samuel Isaly has been a rare constant. Since becoming a drug analyst at age 23, after graduating from the London School of Economics, the manager of the $2 ...

Fortune: Bitter Medicine At Schering-Plough, chronic quality-control problems led to fines, sanctions, and a criminal probe.updated: Mon Oct 14 2002 00:01:00

Springtime on the plains of Midland, Texas, is an asthmatic's nightmare. Along with the tumbleweed and dust, there's always too much pollen floating in the wind. Alexis Milmine feels a stirring in ...

Money Magazine: Edmond Choi & Richard Dahlberg Pelicanupdated: Thu Aug 01 2002 00:01:00

TALK ABOUT A HIDDEN GEM. Pelican's managers don't court media attention. But this small fund (only $117 million in assets) has been quietly beating the pants off the competition for the past 10 yea...

Fortune: Ten Deals We'd Like to Seeupdated: Mon Apr 17 2000 00:01:00

Even through stock market jolts, the merger-and-acquisition frenzy continues unabated. As CEOs struggle to keep pace with changing technology, it gets harder to predict what they'll do. Previously ...

Money Magazine: Edward Chancellor Author of Devil Take the Hindmost: A History of Financial Speculationupdated: Fri Oct 01 1999 00:01:00

STOCKS Bunzl (distributor of packaging material), Iberdrola (Spanish utility), Yalplay (Internet music company), Schering-Plough, Tachihi Enterprise (Japanese real estate manager), Vivendi (French ...

Fortune: FORTUNE 5 Hundred Ranked By Performanceupdated: Mon Apr 26 1999 00:01:00

Size of revenues is the measure we use to rank the FORTUNE 500, but it's not the only one that counts. That's why we also rate the 500 on 12 other performance criteria. Spinoffs and mergers account...

Money Magazine: Michelle R. Clayman Founder and CEO of money-management firm New Amsterdam Partnersupdated: Mon Feb 01 1999 00:01:00


Fortune: Q&A: What Looks Hot at A.G. Edwards DOW 10,000? NOT SO SOONupdated: Mon Aug 03 1998 00:01:00

How does A.G. Edwards outdistance the S&P 500--and many bigger rivals? Stuart Freeman, the strategist who oversees Edwards' focus list, says the firm's St. Louis location probably helps: "We're les...

Fortune: MEDICINE/ HEPATITIS C, THE QUIET EPIDEMICupdated: Mon Aug 07 1995 00:01:00

It's a blood-borne disease, transmitted through transfusions, sex, and shared needles. And it's a silent disease; people can go years before developing any symptoms.

Fortune: GREAT GROWTH STOCKS, FOR A SONGupdated: Mon Sep 21 1992 00:01:00

It's been a rough ride for investors in growth stocks this year. While some of the best, like Wal-Mart Stores, Philip Morris, and Coca-Cola, are still within points of their highs, the rest have be...

Money Magazine: SIX GREAT STOCKS THAT THE PROS HAVE BOUGHT FOR THEIR MOMSupdated: Tue Sep 01 1992 00:01:00

When money managers recommend a stock, it's comforting to know that they own the shares themselves. But with the Dow at near-record heights and consumer confidence at a near-record low, I've been a...

Money Magazine: A FORECAST FOR '89: EXPORTERS WILL PROFIT AS THE DOLLAR DECLINESupdated: Sun Jan 01 1989 00:01:00

In 1985, when the dollar began its downhill schuss against foreign currencies, falling nearly 50%, stocks in leading export companies moved sharply upward (see the chart below). Reason: as goods pr...

Fortune: COVER STORY THE STOCK MARKET TAKES IT IN STRIDEupdated: Mon Oct 28 1985 00:01:00

Though they welcomed the general prospect of a weaker dollar with a brief cheer -- the Dow Jones industrial average rose more than 18 points the day after the Plaza Hotel announcement -- investors ...

Fortune: THE GREAT WAIT FOR INTERFERON Schering-Plough hoped it would be a miracle drug. But interferon hasn't lived up to early expectatupdated: Mon Aug 19 1985 00:01:00

BIOTECHNOLOGY still generates more headlines than profits, and no major drug company knows that better than Schering-Plough. It made one of the earliest and costliest bets on the science -- and has...

Fortune: MADISON AVENUE'S CANCER SELL SPREADS Whether it's sunscreens or cereal, the move is on in print and on TV to push products said updated: Mon Aug 19 1985 00:01:00

CANCER is no longer a taboo subject at advertising agencies. Well before President Reagan's operation for cancer of the colon, Kellogg Co., the U.S. cereal king (1984 sales: $2.6 billion), launched...

Fortune: Signalsupdated: Mon Apr 01 1985 00:01:00

Hoffman-La Roche said it was granted the first U.S. patent for a type of interferon that has been tested for treatment of cancer and as a prevention against the common cold. The New Jersey-based he...

We recommend